MA38717B1 - Antisense oligomers and conjugates targeting pcsk9 - Google Patents

Antisense oligomers and conjugates targeting pcsk9

Info

Publication number
MA38717B1
MA38717B1 MA38717A MA38717A MA38717B1 MA 38717 B1 MA38717 B1 MA 38717B1 MA 38717 A MA38717 A MA 38717A MA 38717 A MA38717 A MA 38717A MA 38717 B1 MA38717 B1 MA 38717B1
Authority
MA
Morocco
Prior art keywords
antisense oligomers
targeting pcsk9
conjugates targeting
conjugates
pck9
Prior art date
Application number
MA38717A
Other languages
French (fr)
Other versions
MA38717A1 (en
Inventor
Nanna Albæk
Maj Hedtjärn
Marie Lindholm
Niels Fisker Nielsen
Jacob Ravn
Andreas Petri
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Priority claimed from PCT/EP2014/063757 external-priority patent/WO2014207232A1/en
Publication of MA38717A1 publication Critical patent/MA38717A1/en
Publication of MA38717B1 publication Critical patent/MA38717B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés oligomères et des conjugués de ceux-ci qui ciblent la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) l'arnm pcsk9 dans une cellule, conduisant à une expression réduite de pcsk9. La réduction de l'expression de pcsk9 est bénéfique pour le traitement de certains troubles médicaux, tels que l'hypercholestérolémie et des troubles associés.The present invention relates to oligomeric compounds and conjugates thereof that target the proprotein convertase subtilisin / kexin type 9 (pcsk9) arnmpcsk9 in a cell, leading to reduced expression of pck9. The reduction of pck9 expression is beneficial for the treatment of certain medical conditions, such as hypercholesterolemia and related disorders.

MA38717A 2013-06-27 2014-06-27 Antisense oligomers and conjugates targeting pcsk9 MA38717B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13174092 2013-06-27
PCT/EP2014/063757 WO2014207232A1 (en) 2013-06-27 2014-06-27 Antisense oligomers and conjugates targeting pcsk9

Publications (2)

Publication Number Publication Date
MA38717A1 MA38717A1 (en) 2018-01-31
MA38717B1 true MA38717B1 (en) 2018-10-31

Family

ID=48672516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38717A MA38717B1 (en) 2013-06-27 2014-06-27 Antisense oligomers and conjugates targeting pcsk9

Country Status (1)

Country Link
MA (1) MA38717B1 (en)

Also Published As

Publication number Publication date
MA38717A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
MA41586A (en) ANTISENSE OLIGOMERS OF TAU PROTEIN AND THEIR USES
MX2019006284A (en) Antisense oligomers and conjugates targeting pcsk9.
MA35365B1 (en) Ringed Pyrimidines substituted and their use
MX2018002158A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder.
EA201490470A1 (en) ANTIBODIES TO PCSK9 AND THEIR APPLICATION
MA35096B1 (en) Cyclopropylamines as lsd1 inhibitors
EA201300471A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS
MA41977B1 (en) Imidazopyrazinones used as pde1 inhibitors
MA37946A1 (en) Treatment of rheumatoid arthritis
MA38957B1 (en) Combinations of Nonsteroidal Anti-Inflammatory (NSAID) and Sigma Receptor Ligand
MA44948A1 (en) Bace 1 inhibitors
MA35457B1 (en) New pyrimethanil formulations and their uses in crop processing
MA50406B1 (en) Magl pyrazole inhibitors
MA39170A1 (en) Serine / threonine kinase inhibitory compounds for their uses in the treatment of cancer
MA37943B1 (en) 2-oxo-2,3-dihydro-indoles for the treatment of disorders of snc
MA39146A1 (en) Combinations of Gabapentanoids and Sigma Receptor Ligands
EA201492271A1 (en) CHROMAN CONNECTIONS
MA39837B1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
FR3019465B1 (en) HYPEROSMOLAR COMPOSITION OF HYALURONIC ACID AND USE THEREOF FOR THE TREATMENT OF CORNEAL EDEMA
MA38717B1 (en) Antisense oligomers and conjugates targeting pcsk9
MA54284A (en) CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
MA39406A1 (en) Prodrug of 1,1 '- (1,6-dioxo-1,6-hexanediyl) bis-d-proline
MA39108A1 (en) New compound for the treatment of severe hypoglycaemia
FR3074421B1 (en) HELICHRYSUM GYMNOCEPHALUM EXTRACT FOR THE TREATMENT AND / OR PREVENTION OF INFLAMMATORY DERMATOSIS
EA201401142A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES, BEARING IT-CONTAINING GROUP, AS KCNQ2 / 3 MODULATORS